IN30718 / InxMed - LARVOL DELTA

InxMed Presents New Data at 14th Annual World ADC Highlighting Synergy of IN10018 with ADCs and Novel Stroma targeting pipeline (PRNewswire) - "InxMed...is presenting preclinical data at 14th Annual World ADC Conference in San Diego regarding IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), to boost efficacy of ADCs, and IN30718，a First-in-Class cancer associated fibroblast (CAF) targeting ADC for high stroma tumors....Preclinical data demonstrated that IN10018 was able to break down the fibrotic barrier, improving penetration of large molecules including ADC. Significant synergy was observed between IN10018 and ADCs such as Enhertu and Trodelvy in stroma rich tumors including pancreatic cancer, TNBC, and ovarian cancer models....IN30718 exhibits robust efficacy in multiple patient derived xenograft (PDX) models of gastrointestinal cancers and is well tolerated by cynomolgus monkeys. IN30718 will be ready for IND submission in mid 2024."

IND • Preclinical • Ovarian Cancer • Pancreatic Cancer • Triple Negative Breast Cancer